Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy

NCT: NCT02304029 · COMPLETED

NCT IDNCT02304029
StatusCOMPLETED
Start Date2015-03-06
Completion2019-11-15

Brief Summary

Epilepsy is a common disease affecting 0.5 to 1% of the general population. Epilepsies refractory to drug treatment lead to increased morbidity, mortality and high costs for public health (representing 75% of the costs associated with epilepsy is among the most costly diseases in Neurology). The only curative therapy is surgical removal or disconnection of the epileptogenic network. To do this, a comprehensive presurgical evaluation is essential to accurately define the location of the epileptogenic zone (EZ) and its relationship with the functional areas that must be preserved. This approach requires in some cases intracerebral EEG recordings. This latter technique, expensive and invasive, remains at present, the standard method in the location of the ZE. In this context, the development of non-invasive and inexpensive methods is a priority in the field. Moreover, many fundamental studies have shown changes in ion homeostasis including sodium associated with hyperexcitability related to epilepsy. The investigators team at CEMEREM, CHU Timone, specialized in the development and validation of innovative methods in MRI, has developed an in vivo sodium MRI acquisition and processing of data unique in France, capable of quantifying the intracerebral sodium concentration in three dimensions in a completely non-invasive and non-irradiating manner

Frequently Asked Questions

What is Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy?

Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy is a clinical trial registered under NCT02304029. Current status: COMPLETED.

What is the status of NCT02304029?

The current status of NCT02304029 (Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy) is: COMPLETED.

When did Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy start?

Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy started on 2015-03-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.